Backround: Depression is a significant concern in clinical and preclinical psychoneurobiological sciences due to its high prevalence and its individual and collective consequences. Identifying efficient biomarkers for accurate diagnosis is crucial, with ideal biomarkers having detectable serum levels and conformational and thermal stability. This study aims to identify stable plasma biomarkers for the diagnosis and prognosis of major depressive disorder, as the pathogenesis of the disorder remains incompletely understood, affecting diagnosis accuracy. Methods: Thus, this study included ten MDD patients and eight healthy controls. The present work analyzed miRNAs in patients with major depressive disorder compared to healthy controls. Results: Eleven specific miRNAs, particularly hsa-miR-874-3p; hsa-let-7d-5p; and hsa-miR-93-3p showed upregulation-type plasma variations in the group of patients with major depressive disorder. miRNA functionality is linked to depressive pathophysiology. Conclusions: This study identifies a “bouquet” of miRNAs with significant upregulation variations in patients with major depressive disorder, suggesting further research to determine their suitability for personalization and evaluation, ultimately becoming integral components of major depression serological evaluations.

Major depressive disorder (MDD) is a complex mental health condition with a multifaceted and incompletely elucidated pathophysiology. MicroRNAs (miRNAs) have emerged as potential biomarkers due to their role in gene regulation and the observed dysregulation in MDD. The aim of this study is to detect the presence of specific molecular diagnostic biomarkers in major depressive disorder. This cross-sectional study analyzed plasma miRNA expression in ten MDD patients and eight healthy controls using real-time PCR. Differentially expressed miRNAs were identified using independent t-tests, and their diagnostic potential was assessed with ROC curve analysis. Fifteen miRNAs exhibited significant dysregulation in MDD patients. Notably, hsa-miR-29c-3p, hsa-miR-376a-3p, hsa-miR-532-5p, and hsa-miR-339-5p showed excellent discriminatory power (AUC > 0.8). This study identifies differentially expressed plasma miRNAs in MDD, suggesting their potential for improved diagnosis and personalized treatment. However, further validation in larger cohorts and investigation into their functional roles are warranted.

Background/Objectives: We assessed the frequency, timing and management of carbapenem-resistant Acinetobacter baumannii (CRAB) isolation and its association with in-hospital mortality in adults hospitalized with COVID-19. Methods: This retrospective single-center cohort study included all 395 adults admitted from 12 July to 25 September 2022. The primary analysis compared in-hospital mortality by CRAB isolation in the full cohort, with Firth-penalized adjustment for age and admission SpO₂. Treatment and case-level data, complete for 95 chart-verified patients, were analyzed secondarily; isolates were classified by onset (NHSN criteria) and respiratory isolates adjudicated as infection or colonization. Results: CRAB was isolated in 33/395 patients (8.4%). Mortality was 36.4% (12/33) with CRAB isolation versus 11.6% (42/362) without (crude OR 4.35, 95% CI 1.81–10.02; adjusted OR 3.82, 95% CI 1.62–9.02). In the detailed-data subset (8/95 with CRAB), isolates were first detected on hospital days 2–6 and four were community-onset; four of seven respiratory isolates represented colonization. All eight received empirical carbapenem plus colistin after specimen collection, including full 9–10-day colistin-based courses in the four colonized patients. Conclusions: CRAB isolation was associated with higher in-hospital mortality after adjustment for baseline severity, but selective sampling precludes causal inference. Early detection suggests frequent carriage on admission; treatment of colonization was the main stewardship target, supporting admission screening and diagnostic stewardship.

Background/Objectives: Clostridioides difficile infection (CDI) is an increasingly recognised nosocomial complication in patients hospitalised with coronavirus disease 2019 (COVID-19), driven by broad-spectrum antibiotic exposure, corticosteroid use, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related intestinal dysbiosis. The contribution of underlying cardiovascular comorbidities, particularly heart failure, to CDI susceptibility in hospitalised COVID-19 patients remains insufficiently characterised. We aimed to evaluate the prevalence, risk factors, and clinical impact of CDI in hospitalised COVID-19 patients at a tertiary Romanian infectious diseases centre, with a specific focus on cardiovascular disease and modifiable antimicrobial-prescribing factors. Methods: This single-centre retrospective observational cohort study enrolled 395 consecutive adult patients hospitalised with SARS-CoV-2 infection confirmed by reverse transcription polymerase chain reaction (RT-PCR) at the “Victor Babeș” Clinical Hospital for Infectious Diseases and Pneumophthisiology, Timișoara, Romania, between 1 March 2020 and 31 December 2024. Patients were stratified into a CDI group (n = 24) and a non-CDI group (n = 371) on the basis of hospital-onset CDI. Demographic, clinical, laboratory, therapeutic, and outcome variables were extracted from electronic medical records. Continuous variables were compared using Student’s independent-samples t-test, categorical variables using Fisher’s exact test; odds ratios (ORs) with exact 95% confidence intervals (CIs) were computed for all binary comparisons, and a parsimonious multivariable logistic regression was used to adjust the antibiotic-exposure effect for age. Temporal relationships between CDI onset and sepsis documentation were also analysed. A two-sided p-value < 0.05 was considered statistically significant. Results: CDI was identified in 24 patients (prevalence 6.1%). The CDI and non-CDI groups were comparable in age (71.1 ± 10.2 vs. 71.7 ± 11.4 years; p = 0.817), sex distribution (50.0% vs. 45.8% female; p = 0.833), and vaccination status (p = 0.383). Heart failure prevalence did not differ between groups (29.2% vs. 26.7%; OR 1.13, 95% CI 0.46–2.81; p = 0.813). Any antibiotic therapy was strongly associated with CDI (95.8% vs. 70.6%; OR 9.57, 95% CI 1.28–71.74; p = 0.004), as was longer duration of antibiotic therapy (8.1 ± 2.2 vs. 5.2 ± 3.7 days; p < 0.001). In the multivariable model, each additional day of antibiotic therapy was independently associated with a 13.6% increase in the odds of CDI (adjusted OR 1.14 per day, 95% CI 1.03–1.26; p = 0.013) after adjustment for age. Piperacillin/tazobactam accounted for 65.2% (15/23) of the recorded pre-CDI broad-spectrum antibiotic regimens among antibiotic-exposed CDI patients. Documented sepsis was substantially more frequent in CDI patients (95.8% vs. 15.4%; p < 0.001) and length of hospitalisation was prolonged (15.6 ± 8.2 vs. 12.0 ± 8.1 days; p = 0.038). In-hospital mortality did not differ significantly (4.2% vs. 7.5%; p = 1.000). Conclusions: Hospital-onset CDI complicated 6.1% of hospitalised COVID-19 admissions and was independently associated with the cumulative duration of antibiotic therapy. Heart failure was not significantly associated with CDI in this cohort; however, given the limited number of CDI events, this should be interpreted as absence of evidence rather than evidence of absence. CDI was also associated with prolonged hospitalisation and high co-occurrence of documented sepsis, although causality cannot be inferred from the retrospective design. These findings support strengthened antibiotic stewardship and targeted CDI surveillance in COVID-19 inpatient wards.

Blood cultures are frequently obtained in hospitalized patients with COVID-19, although the diagnostic yield and clinical meaning of culture positivity vary markedly according to case mix, disease severity, and timing of sampling. Omicron-era data remain comparatively limited. We aimed to characterize blood-culture positivity, pathogen distribution, inflammatory correlates, antimicrobial exposure, and short-term outcomes in a homogeneous cohort hospitalized during the SARS-CoV-2 Omicron BA.5 wave. This retrospective observational study included 395 patients hospitalized with SARS-CoV-2 infection between 12 July and 25 September 2022. Patients were categorized as blood-culture positive when a named bacterial species was recorded and as culture negative when “No growth” was documented. Continuous variables were compared using the Mann–Whitney U test and categorical variables using Fisher’s exact or chi-square tests, as appropriate. A parsimonious multivariable logistic regression model was used to explore factors independently associated with blood-culture positivity. Blood cultures were positive in 89/395 patients (22.5%). Gram-positive organisms accounted for 52.8% of positive cultures and Gram-negative organisms for 47.2%. The most frequent isolates were Streptococcus pneumoniae (20.2% of positive cultures), Enterococcus faecalis (18.0%), Klebsiella pneumoniae (18.0%), Staphylococcus aureus (14.6%), Escherichia coli (14.6%), and Pseudomonas aeruginosa (14.6%). Compared with patients with no growth, those with positive cultures had higher admission leukocyte counts (median 13.42 vs. 11.22 × 10⁹/L; p < 0.001), C-reactive protein (116.15 vs. 105.50; p = 0.007), and interleukin-6 (17.24 vs. 9.39; p = 0.027). A documented sepsis diagnosis was more frequent in the culture-positive group (48.3% vs. 28.1%; OR 2.39, 95% CI 1.47–3.88; p < 0.001). Mortality was numerically higher with culture positivity (20.2% vs. 14.4%) but did not reach statistical significance (p = 0.188). In the adjusted model, higher leukocyte count remained independently associated with culture positivity (aOR 1.10 per 1 × 10⁹/L, 95% CI 1.05–1.15; p < 0.001), while vaccination status showed an inverse exploratory association (aOR 0.58, 95% CI 0.35–0.96; p = 0.033). The exploratory model AUC was 0.672 (bootstrap 95% CI 0.608–0.731); calibration was not assessed. Blood-culture positivity was common in this hospitalized BA.5 cohort and showed a nearly balanced Gram-positive/Gram-negative distribution. Leukocytosis and clinically documented sepsis were the clearest correlates of positivity, whereas mortality did not differ significantly. These findings support selective blood-culture use driven by bacterial infection signals and emphasize the need to connect antimicrobial decisions to microbiological evidence.

Background and Objectives: Secondary bloodstream infection in patients hospitalized with coronavirus disease 2019 (COVID-19) can lengthen admission and increase antimicrobial exposure, yet pathogen-specific evidence from the Omicron period is scarce. We examined how often Klebsiella pneumoniae was recovered from blood among adults admitted with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection during the Omicron BA.5 wave, and which clinical features and outcomes accompanied it. Materials and Methods: This retrospective single-center cohort comprised 395 adults admitted in Timișoara, Romania, from 12 July to 25 September 2022. Patients with K. pneumoniae in blood culture were compared with all remaining patients, whether their cultures showed no growth or another pathogen. Groups were compared with the Mann–Whitney U and Fisher’s exact tests. The association between K. pneumoniae and a hospital stay of at least 14 days was estimated with Firth penalized logistic regression, adjusted for age, sex, and admission oxygen saturation. Results: Blood cultures grew K. pneumoniae in 16 patients (4.1%), another pathogen in 73 (18.5%), and nothing in 306 (77.5%). Median length of stay was 17.5 days (IQR (interquartile range) 9.8–25.2) with K. pneumoniae and 9.0 days (IQR 7.0–16.0) in the rest of the cohort (p = 0.006); a stay of at least 14 days occurred in 56.3% versus 28.0% (unadjusted OR 3.31, p = 0.022). The association persisted after adjustment (Firth adjusted OR 3.18, 95% CI 1.14–8.87; p = 0.027; maximum-likelihood estimate 3.25, 95% CI 1.16–9.12; p = 0.025). In-hospital death occurred in 1 of 16 exposed patients (6.3%) and in 61 of 379 others (16.1%; Fisher’s exact p = 0.485); with a single exposed death, the age- and sex-adjusted Firth estimate was imprecise (adjusted OR 0.48, 95% CI 0.04–2.21). Conclusions: K. pneumoniae bloodstream isolation was infrequent in this Omicron BA.5 cohort but was accompanied by a markedly longer hospital stay. Causality and an effect on mortality cannot be inferred: culture dates, place of acquisition, device exposure, and isolate susceptibility were not available, the untimed exposure is prone to immortal-time bias, and no non-COVID-19 comparator was studied. Prospective surveillance combining time-stamped microbiology with resistance phenotyping is needed.